Showing results (1-10 of 406) with videos related to
Sort By:
Pageof 41
Clinical Breast Cancer|December 15, 2010
CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancerJosé Baselga, Sandra M SwainNature Reviews. Cancer|June 19, 2009
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3José Baselga, Sandra M SwainJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancerJosé Baselga, Javier Cortés, Seock-Ah Im, et al.Breast Cancer Research and Treatment|October 17, 2013
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)David Miles, José Baselga, Dino Amadori, et al.The Oncologist|May 30, 2014
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRASandra M Swain, Young-Hyuck Im, Seock-Ah Im, et al.The Oncologist|February 1, 2011
Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancerJosé BaselgaThe Oncologist|August 31, 2002
Why the epidermal growth factor receptor? The rationale for cancer therapyJosé BaselgaThe Oncologist|March 12, 2013
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III studySandra M Swain, Michael S Ewer, Javier Cortés, et al.Pageof 41